標(biāo)題: Titlebook: Drug Development; Molecular Targets fo Timothy S. Gaginella,Antonio Guglietta Book 2000 Springer Science+Business Media New York 2000 cytok [打印本頁(yè)] 作者: papertrans 時(shí)間: 2025-3-21 17:28
書(shū)目名稱(chēng)Drug Development影響因子(影響力)
作者: 確定 時(shí)間: 2025-3-21 22:32 作者: Bravura 時(shí)間: 2025-3-22 03:51 作者: 小卒 時(shí)間: 2025-3-22 05:39 作者: 慷慨不好 時(shí)間: 2025-3-22 10:58 作者: 一加就噴出 時(shí)間: 2025-3-22 13:54 作者: 一加就噴出 時(shí)間: 2025-3-22 17:33 作者: 心痛 時(shí)間: 2025-3-22 23:20
Opioid Receptors, the most used analgesics. Besides a predominant role in pain control (both somatic and visceral pain), opioids and opioid receptors have a broad spectrum of actions, including modulations of reinforcement and reward pathways, neurotransmitter release, neuroendocrine functions, as well as gastrointe作者: 爭(zhēng)吵 時(shí)間: 2025-3-23 02:19
Ute Winkels,Yoko Schlütermann-Sugiyama. In this chapter, the biological actions of the eicosanoids are reviewed, as are the enzymes through which they are formed, and the receptors through which they act. The potential of drugs that block the activity of these enzymes or the eicosanoid receptors is reviewed, particularly with respect to作者: 浮雕寶石 時(shí)間: 2025-3-23 06:01
Ute Winkels,Yoko Schlütermann-Sugiyamadies on the role of NO in the GI tract, especially as it relates to maintenance of physiological function and mucosal integrity; the therapeutic potential of agents that modulate the NO system will also be discussed.作者: obstinate 時(shí)間: 2025-3-23 12:28
https://doi.org/10.1007/978-3-663-11747-6 the field of animal models of IBD that has occurred in the past decade has considerably expanded the involvement of CKs in intestinal inflammation. Therefore, IBD represents the ideal clinical and experimental model to describe CK abnormalities in the inflamed GI system, and to discuss the related 作者: 拾落穗 時(shí)間: 2025-3-23 15:26 作者: mosque 時(shí)間: 2025-3-23 21:24 作者: 撕裂皮肉 時(shí)間: 2025-3-23 23:20
Hans-Hermann Braess,Ulrich Seiffert994a, 1994b) and on CCK receptors (Dourish and Hill, 1987; Jensen et al., 1990; Woodruff and Hughes, 1991; Silvente-Poirot et al., 1993; Williams and Blevins, 1993; D’ Amato et al., 1994; Rasmussen, 1995; Wang, 1995) are available. Moreover, Adler and Beglinger (1991), provide comprehensive coverage作者: 凹處 時(shí)間: 2025-3-24 04:12 作者: 厭煩 時(shí)間: 2025-3-24 09:31
The Arachidonic Acid Pathway,. In this chapter, the biological actions of the eicosanoids are reviewed, as are the enzymes through which they are formed, and the receptors through which they act. The potential of drugs that block the activity of these enzymes or the eicosanoid receptors is reviewed, particularly with respect to作者: myriad 時(shí)間: 2025-3-24 12:20
Therapeutic Implications of the Nitric Oxide Pathway in Gastrointestinal Diseases,dies on the role of NO in the GI tract, especially as it relates to maintenance of physiological function and mucosal integrity; the therapeutic potential of agents that modulate the NO system will also be discussed.作者: 改變 時(shí)間: 2025-3-24 18:54 作者: negotiable 時(shí)間: 2025-3-24 19:09
Peptide Growth Factors in Gastrointestinal Disorder Therapeutics,growth factor-a (TGF-a), for example, in addition to stimulating proliferation of epithelial cells of the gastrointestinal (GI) tract, are also potent inhibitors of gastric acid secretion (Elder et al., 1975; Koffman et al., 1982; Guglietta and Lesch, 1993; Guglietta et al., 1994).作者: 雕鏤 時(shí)間: 2025-3-25 02:24 作者: 男生戴手銬 時(shí)間: 2025-3-25 06:53
CCKA Receptors in Gastrointestinal Disorders,994a, 1994b) and on CCK receptors (Dourish and Hill, 1987; Jensen et al., 1990; Woodruff and Hughes, 1991; Silvente-Poirot et al., 1993; Williams and Blevins, 1993; D’ Amato et al., 1994; Rasmussen, 1995; Wang, 1995) are available. Moreover, Adler and Beglinger (1991), provide comprehensive coverage作者: Fortuitous 時(shí)間: 2025-3-25 07:46 作者: 鍵琴 時(shí)間: 2025-3-25 12:25 作者: certain 時(shí)間: 2025-3-25 15:55
and peptic ulcer disease has led to even more effective pharmacotherapeutic regimens. Our intent in Drug Development: Molecular Targets for GI Diseases is to bring together hands-on experts to review promising areas of gastrointestinal pharmacology. The contemporary topics covered, from a mechanistic viewpoi978-1-61737-087-8978-1-59259-202-9作者: AWE 時(shí)間: 2025-3-25 20:57 作者: 輕浮女 時(shí)間: 2025-3-26 03:56 作者: 避開(kāi) 時(shí)間: 2025-3-26 06:54
ointestinal disorders. Important new drugs have emerged through the collaborative and complementary efforts of basic scientists, clinicians, and clinical researchers in academia and the pharmaceutical industry. The challenge has been exciting, with a few surprises along the way. Consider peptic ulce作者: 痛苦一生 時(shí)間: 2025-3-26 12:08 作者: 行業(yè) 時(shí)間: 2025-3-26 15:53 作者: Compatriot 時(shí)間: 2025-3-26 19:47
The Histamine H3 Receptor,Histamine is widely distributed in the body, although with marked quantitative differences in the various species and tissues, and it produces a variety of biological effects by interacting with specific receptors on the surface of target cells.作者: 顯赫的人 時(shí)間: 2025-3-26 20:57
Ute Winkels,Yoko Schlütermann-Sugiyaman then be metabolized via several enzymes to yield a vast array of vasoactive and immunomodulatory substances, termed “eicosanoids” (Fig. 1). Included in this group are the prostaglandins (PGs), leukotrienes (LTs) and thromboxanes (TXs). In general, eicosanoids have a short half-life (seconds to min作者: 開(kāi)頭 時(shí)間: 2025-3-27 02:01
Ute Winkels,Yoko Schlütermann-Sugiyamasiologic roles for NO have been identified, including those of a vasodilator, neurotransmitter, antimicrobial agent, immunomodulator, and intracellular signaling molecule (Moncada et al., 1991; Moncada and Higgs, 1995; Whittle, 1994). It can be formed in a wide range of cell types, such as the endot作者: Mosaic 時(shí)間: 2025-3-27 05:56
https://doi.org/10.1007/978-3-663-11747-6nes (CKs) are involved in essentially all of these GI disorders, but they play a particularly dominant role in illnesses whose clinical symptoms are the result of immune-mediated, persistent inflammatory processes. Typical examples include chronic gastritis, celiac disease (gluten-sensitive enteropa作者: Medicaid 時(shí)間: 2025-3-27 10:04
Einführung in die Problemstellungand differentiation. In contrast to the classical hormones that are produced and secreted by specific cells, PGFs are usually synthesized by cells of a variety of different tissues, and often exert their pharmacological effects on target cells located not far from the site of release (paracrine resp作者: 譏笑 時(shí)間: 2025-3-27 17:07
Einführung in die Problemstellung different from any of the endogenous compounds known at that time. Quantitative estimations of the novel principle were made by comparing the activity of extracts with the effect of a standard preparation referred to as “P” on the tracings and in the protocols, so that, since 1934, the term “substa作者: 為敵 時(shí)間: 2025-3-27 20:01
Hans-Hermann Braess,Ulrich Seiffert step has been the development of potent and specific peptide receptor antagonists, which not only became important experimental tools for elucidating the physiological roles of peptide hormones, but also in defining the contribution of peptide hormones to disease states, but they may even ultimatel作者: 胖人手藝好 時(shí)間: 2025-3-28 00:04
Hans-Hermann Braess,Ulrich Seiffertfor the focus on 5-HT is its strategic location in enterochromaffin cells (Erspamer, 1996) which are in close proximity to the mucosal sensory nerve endings, and in interganglionic neurons, which synapse on motor excitatory and motor inhibitory neurons (Gershon and Ross, 1966; Gershon, 1977; Furness作者: 涂掉 時(shí)間: 2025-3-28 02:08 作者: 演講 時(shí)間: 2025-3-28 08:19 作者: Calibrate 時(shí)間: 2025-3-28 14:19
978-1-61737-087-8Springer Science+Business Media New York 2000
